Tirzepatide for medics: what clinicians need to know about this dual-agonist medicine

How does the dual GIP and GLP-1 mechanism actually differ from earlier GLP-1 medicines?

Single-pathway GLP-1 receptor agonists (semaglutide being the most familiar example) reduce appetite primarily by slowing gastric emptying and acting on hypothalamic satiety circuits. Tirzepatide does this too, but also engages the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP has historically been associated with nutrient-stimulated insulin secretion and, in adipose tissue, with lipid metabolism. The combined activation appears to produce a greater reduction in energy intake and, in the SURMOUNT trial programme, consistently larger average weight losses than those seen with earlier single-agonist agents.

In the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine (2025), tirzepatide produced statistically greater average weight reduction than semaglutide 2.4 mg over 72 weeks in adults with obesity and no diabetes. NICE's committee, in its appraisal of tirzepatide (TA1026), acknowledged that indirect comparisons also favour tirzepatide, while noting that head-to-head evidence was limited at the time of appraisal. The SURMOUNT-5 data have since strengthened that picture.

For clinicians familiar with the GLP-1 class, the practical distinction is that a patient who has plateaued on semaglutide may respond differently to tirzepatide because of the additional receptor pathway — though switching decisions remain a matter of individual clinical judgement and should be discussed with the patient's prescriber. You can find a broader overview of GLP-1 medications alongside tirzepatide's place in the class in our educational content.

What does the SURMOUNT trial programme tell us about expected weight outcomes?

SURMOUNT-1 randomised 2,539 adults with a BMI of 30 or above (or 27 with at least one weight-related comorbidity, without diabetes) to one of three tirzepatide doses or placebo over 72 weeks, alongside lifestyle intervention. Average body-weight reduction was approximately 15% at 5 mg, 19.5% at 10 mg, and 20–21% at 15 mg. Some analyses of the 15 mg arm report figures close to 22.5%, though the primary ITT estimate sits around 20–21%, the range to cite in a clinical context. Placebo participants lost around 3%.

SURMOUNT-2 examined the population with type 2 diabetes and found similarly meaningful reductions (around 12–14% at higher doses), consistent with tirzepatide's dual diabetes and obesity licence. The total SURPASS plus SURMOUNT programme involved more than 10,000 participants across obesity and diabetes indications.

What these figures represent in practice is a substantial step beyond what lifestyle intervention alone typically achieves, and meaningful even against older pharmacotherapy options. The relevant caveat for any clinical communication is that these were controlled trial conditions with regular follow-up and dietary support, real-world outcomes vary, and treatment works best alongside reduced-calorie eating and increased activity. Patients considering private treatment can read a thorough patient-level overview of tirzepatide that we keep updated against current UK guidance.

What are the key safety considerations medics should be aware of for tirzepatide?

The side-effect profile is dominated by gastrointestinal symptoms: nausea, vomiting, diarrhoea, constipation, reflux and burping. These are most pronounced after dose initiation and following each upward titration step, and they tend to settle within one to two weeks for most patients. Starting at 2.5 mg (a tolerability dose rather than a therapeutic target) and titrating slowly is the mechanism the SmPC relies on to manage this.

In January 2026, the MHRA issued a Drug Safety Update covering the whole GLP-1 class, highlighting acute pancreatitis as an infrequent but potentially serious adverse event. Clinicians should advise patients to seek urgent medical assessment for severe or persistent abdominal pain, particularly pain that radiates to the back. Gallbladder events, including cholelithiasis, are also represented in the trial data at a higher rate than placebo.

For women of childbearing age, tirzepatide slows gastric emptying in a way that can reduce absorption of oral contraceptives. UK guidance recommends adding a non-oral contraceptive method for the first four weeks of treatment and for four weeks after each dose increase. Transdermal HRT (patches or gels) is preferred over oral formulations for the same reason, per NHS England advice. Tirzepatide carries a Black Triangle (▼) designation, meaning it is subject to additional monitoring by the MHRA. Suspected adverse effects should be reported via the MHRA Yellow Card scheme. It is not licensed for use in pregnancy, breastfeeding, or in those actively trying to conceive, and is not licensed for under-18s.

How is tirzepatide positioned within the current UK prescribing landscape?

On the NHS, tirzepatide became available in primary care from April 2026 under the updated GP contract, subject to the phased eligibility criteria in NICE TA1026. The current cohort (as of summer 2026) covers adults with a BMI of 40 or above alongside four or more of five specified comorbidities (hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, type 2 diabetes). A second cohort covering BMI 35–39.9 with four or more conditions was activated in June 2026, with further phases planned through 2027. Ethnic-background thresholds are 2.5 kg/m² lower throughout. GP practice participation remains optional, so access varies by area.

Private prescribing has run ahead of NHS availability, giving patients an alternative route when they fall outside current NHS cohorts or prefer not to wait. Eli Lilly raised the UK list price of tirzepatide significantly from September 2025, and patients sometimes ask whether Mounjaro or tirzepatide is the right way to think about what they are being prescribed, so it is worth clarifying that distinction clearly. For a detailed cost comparison in context, our Mounjaro overview covers pricing honestly, including what a private prescription should include.

The pen itself contains four weekly doses and is stored in the fridge; many patients keep it in the fridge door so it's visible and easy to remember alongside a routine. For medics making referral decisions or answering patient questions about private options, our clinical team page sets out how we structure prescribing oversight, and our lead prescriber's profile is available at the prescriber's page. Patients who want to explore whether they are clinically suitable for private treatment can be pointed toward a free consultation, where a GPhC-registered Independent Prescriber reviews their history before any prescription is issued. Those who would like to understand the full range of tirzepatide medicines available through our pharmacy, including formulations and dose options, will find that detail in our dedicated medicines section, and patients specifically asking about the lower starting doses can be directed to our tirzepatide l page, which covers that part of the titration pathway in more depth.